HC Wainwright Has Negative Estimate for OmniAb Q3 Earnings

OmniAb, Inc. (NASDAQ:OABI) – HC Wainwright dropped their Q3 2026 EPS estimates for OmniAb in a report released on Friday, August 7th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.11) per share for the quarter, down from their prior forecast of ($0.10). The consensus estimate for OmniAb’s current full-year earnings is ($0.39) per share. HC Wainwright also issued estimates for OmniAb’s FY2026 earnings at ($0.34) EPS, FY2027 earnings at ($0.18) EPS, FY2028 earnings at ($0.06) EPS, FY2029 earnings at ($0.02) EPS and FY2030 earnings at $0.05 EPS.

OmniAb (NASDAQ:OABI) last released its earnings results on Thursday, August 6th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.07. The company had revenue of $13.41 million for the quarter, compared to analysts’ expectations of $4.69 million. OmniAb had a negative net margin of 115.12% and a negative return on equity of 16.59%.

Separately, Weiss Ratings downgraded OmniAb from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, OmniAb has a consensus rating of “Hold”.

OmniAb Stock Performance

Shares of OABI stock opened at $3.39 on Tuesday. OmniAb has a 52-week low of $1.30 and a 52-week high of $3.44. The firm has a market capitalization of $490.80 million, a PE ratio of -9.42 and a beta of 0.45. The stock has a fifty day simple moving average of $2.28 and a two-hundred day simple moving average of $1.97.

Institutional Trading of OmniAb

A number of institutional investors and hedge funds have recently bought and sold shares of OABI. BlackRock Inc. bought a new position in shares of OmniAb during the 2nd quarter valued at about $21,888,000. Deutsche Bank AG bought a new stake in shares of OmniAb in the second quarter worth about $248,000. Rice Hall James & Associates LLC purchased a new stake in shares of OmniAb in the second quarter worth about $6,422,000. Bank of New York Mellon Corp purchased a new stake in shares of OmniAb in the second quarter worth about $783,000. Finally, Bank of America Corp DE boosted its stake in OmniAb by 46.4% during the first quarter. Bank of America Corp DE now owns 121,656 shares of the company’s stock valued at $191,000 after buying an additional 38,568 shares during the last quarter. 72.08% of the stock is currently owned by institutional investors.

About OmniAb

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.